Legal Opinion
Novartis Pharmaceuticals Corp v. West-Ward Pharmaceuticals
Court of Appeals for the Federal Circuit
Decided May 13, 2019No. 2018-1434PublishedCited by 11 opinions
1Opinion of the Court
Stoll, Circuit Judge.
West-Ward Pharmaceuticals International Ltd ("West-Ward") 1 appeals the decision of the United States District Court for the District of Delaware holding that claims 1-3 of U.S. Patent No. 8,410,131 would not have been obvious in view of the prior art. We conclude that the district court did not err in its nonobviousness determination and affirm.
BACKGROUND
Novartis Pharmaceuticals Corp. and Novartis AG (collectively, "Novartis") own the '131 patent, which claims methods of using the compound everolimus to treat advanced renal cell carcinoma ("RCC"). Everolimus is the…
2Cases cited18 opinions
- United States v. United States Gypsum Co.Supreme Court of the United States · 1948
- Graham v. John Deere Co. of Kansas CitySupreme Court of the United States · 1966
- KSR International Co. v. Teleflex Inc.Supreme Court of the United States · 2007
- Pfizer, Inc. v. Apotex, Inc.Court of Appeals for the Federal Circuit · 2007
- Procter & Gamble Co. v. Teva Pharmaceuticals USA, Inc.Court of Appeals for the Federal Circuit · 2009
13 more not listed; retrieve them via the Exa API.
3Cited by11 opinions
- Elekta Limited v. Zap Surgical Systems, Inc.Court of Appeals for the Federal Circuit · 2023
- Carefirst of Maryland, Inc., et al. v. Johnson & Johnson and Janssen Biotech, Inc.District Court, E.D. Virginia · 2025
- Eli Lilly and Company v. Teva PharmaceuticalsCourt of Appeals for the Federal Circuit · 2021
- Honeywell International Inc. v. 3g Licensing, S.A.Court of Appeals for the Federal Circuit · 2025
- Immunogen, Inc. v. StewartCourt of Appeals for the Federal Circuit · 2025
6 more not listed; retrieve them via the Exa API.